Posted by Michael Wonder on 07 May 2020
NICE draft guidance recommends new treatment option for people with early breast cancer
7 May 2020 - NICE has today published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer.
Around 7,000 people diagnosed each year in England with early breast cancer have HER2-positive disease.
Trastuzumab emtansine costs on average £51,000 per patient for a course of treatment at its full list price. The company has agreed a commercial arrangement which makes trastuzumab emtansine available to the NHS with a confidential discount.
